Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Ludovica Papotto
Observed name:
L. Papotto
Institutions:
Vita-Salute San Raffaele University,
IRCCS Ospedale San Raffaele
Observed institutions:
Vita-Salute San Raffaele University,
IRCCS Ospedale San Raffaele
ORCID:
0009-0002-2545-8213
Observed ORCID:
0009-0002-2545-8213
OpenAlex ID:
A5107401068
Impact of platinum-based chemotherapy and CTLA-4 inhibition on acquired resistance to first-line anti-PD-1/PD-L1 agents in non-small cell lung cancer: a systematic review and reconstructed individual patient data analysis
2025
·
Sara Oresti
, Fabio Salomone
, et al.
·
EClinicalMedicine
·
5
PDF
1232P Assessing uncertainty and vulnerability of clinical trials with immune-checkpoint inhibitors and chemotherapy (ICI+CT) in early stage non-small cell lung cancer (NSCLC) by informative censoring and survival inferred fragility index (SIFI)
2024
·
A. Nuccio
, F. Salomone
, et al.
·
Annals of Oncology
·
1
PDF
Hyperprogression Upon Cemiplimab Alone or With Short Course Chemotherapy in PD-L1 ≥ 50% Non–small Cell Lung Cancer: A Biomarker Guided Multicenter International Phase 2 Trial—HYPERBOLIC Study
2026
·
Ludovica Mollica
, Elena Tassi
, et al.
·
Clinical Lung Cancer
AI-HOPE lung cancer: a multicenter real-world registry integrating artificial intelligence for metastatic non-small-cell lung cancer
2026
·
F.R. Ogliari
, M. Ferrara
, et al.
·
ESMO Real World Data and Digital Oncology
PDF
Benchmarking Missing-Data-Native Survival Models in a Real-World Metastatic NSCLC Cohort — the AI-HOPE Lung Cancer Study
2026
·
Francesca Rita Ogliari
, Donato Tiano
, et al.
·
Research Square
PDF
562eP Tumor, host and treatment related predictive factors for immune-related adverse events (irAEs) in non-small cell lung cancer (NSCLC) patients (pts) treated with immune checkpoint inhibitors (ICI)
2026
·
F.M. Venanzi
, D. Zotti
, et al.
·
ESMO Open
108P Time-to-event (TTE) machine learning models (ML-m) for survival prediction in patients with advanced non-small cell lung cancer (aNSCLC) receiving first-line (chemo-)immunotherapy
2025
·
F.R. Ogliari
, D. Tiano
, et al.
·
ESMO Real World Data and Digital Oncology
27P: Impact of platinum-based chemotherapy (CT) on acquired resistance (AR) to first-line immunecheckpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC): Individual patient data metanalysis
2025
·
S. Oresti
, F. Salomone
, et al.
·
Journal of Thoracic Oncology
PDF
P2.11B.04 Chemotherapy Increases Acquired Resistance to Immunotherapy in NSCLC: A Metanalysis of Aggregate and Individual Patient Data
2024
·
S. Oresti
, A. Nuccio
, et al.
·
Journal of Thoracic Oncology
PDF
Show more works
View as search
Works count:
9
Citation count:
6
H-index:
1
I10-index:
Year
Topic
Type